Tamoxifen Other names: Tamoxifen citrate

Chemical formula: C₂₆H₂₉NO  Molecular mass: 371.515 g/mol  PubChem compound: 2733526

Interactions

Tamoxifen interacts in the following cases:

CYP2D6 inhibitors

Pharmacokinetic interaction between CYP2D6 inhibitors and tamoxifen, showing a 65-75% reduction in plasma levels of one of the more active forms of tamoxifen, i.e. endoxifen, has been reported in the literature. Reduced efficacy of tamoxifen has been reported with concomitant usage of some SSRI antidepressants in some studies. As a reduced effect of tamoxifen cannot be excluded, co-administration with potent CYP2D6 inhibitors (including paroxetine) should whenever possible be avoided.

CYP3A4 inducers

As tamoxifen is metabolised by cytochrome P450 3A4, care is required when co-administering with drugs, such as rifampicin, known to induce this enzyme as tamoxifen levels may be reduced. The clinical relevance of this reduction is unknown.

Oral hormonal contraceptives

There is some evidence that hormone replacement therapy may reduce the effectiveness of tamoxifen, and the concomitant use of tamoxifen and oral hormonal contraceptives is not recommended. Therefore, the use of hormone replacement therapy or oral hormonal contraceptives to manage tamoxifen side effects is not recommended.

Suppression of menstruation

Menstruation is suppressed in a proportion of pre-menopausal women receiving tamoxifen for the treatment of breast cancer.

Endometrial hyperplasia, endometrial cancer

An increased incidence of endometrial changes including hyperplasia, polyps, cancer and uterine sarcoma (mostly malignant mixed Mullerian tumours), has been reported in association with tamoxifen treatment. The underlying mechanism is unknown but may be related to the oestrogen-like effect of tamoxifen.

There are several factors that influence the risk of developing endometrial cancer, with the majority of risk factors affecting oestrogen levels. Therefore, tamoxifen treatment may increase the incidence of endometrial cancer. In addition, other risk factors include obesity, nulliparity, diabetes mellitus, polycystic ovary syndrome and oestrogen-only HRT. There is also the general risk for endometrial cancer with increasing age. Any patient receiving or having previously received tamoxifen who report abnormal gynaecological symptoms, especially non-menstrual vaginal bleeding, or who presents with menstrual irregularities, vaginal discharge and symptoms such as pelvic pain or pressure should be promptly investigated.

Breast reconstruction

In delayed microsurgical breast reconstruction, tamoxifen may increase the risk of microvascular flap complications.

Venous thromboembolism (VTE)

A 2-3-fold increase in the risk for VTE has been demonstrated in healthy tamoxifen-treated women.

In patients with breast cancer, prescribers should obtain careful histories with respect to the patient’s personal and family history of VTE. If suggestive of a prothrombotic risk, patients should be screened for thrombophilic factors. Patients who test positive should be counselled regarding their thrombotic risk. The decision to use tamoxifen in these patients should be based on the overall risk to the patient. In selected patients, the use of tamoxifen with prophylactic anticoagulation may be justified.

The risk of VTE is further increased by severe obesity, increasing age and all other risk factors for VTE. The risks and benefits should be carefully considered for all patients before treatment with tamoxifen. In patients with breast cancer, this risk is also increased by concomitant chemotherapy. Long-term anti-coagulant prophylaxis may be justified for some patients with breast cancer who have multiple risk factors for VTE.

Surgery and immobility: For patients being treated for infertility, tamoxifen should be stopped at least 6 weeks before surgery or long-term immobility (when possible) and re-started only when the patient is fully mobile. For patients with breast cancer, tamoxifen treatment should only be stopped if the risk of tamoxifen-induced thrombosis clearly outweighs the risks associated with interrupted treatment. All patients should receive appropriate thrombosis prophylactic measures and should include graduated compression stockings for the period of hospitalisation, early ambulation, if possible, and anti-coagulant treatment.

If any patient presents with VTE, tamoxifen should be stopped immediately and appropriate anti-thrombosis measures initiated. In patients being treated for infertility, tamoxifen should not be re-started unless there is a compelling alternative explanation for their thrombotic event. In patients receiving tamoxifen for breast cancer, the decision to re-start tamoxifen should be made with respect to the overall risk for the patient. In selected patients with breast cancer, the continued use of tamoxifen with prophylactic anticoagulation may be justified.

All patients should be advised to contact their doctors immediately if they become aware of any symptoms of VTE.

Pregnancy

Tamoxifen is contra-indicated in pregnancy. There have been a small number of reports of spontaneous abortions, birth defects and foetal deaths after women have taken tamoxifen although no causal relationship has been established.

Reproductive toxicology studies in rats, rabbits and monkeys have shown no teratogenic potential.

In rodent models of foetal reproductive tract development, tamoxifen was associated with changes similar to those caused by oestradiol, ethinylestradiol, clomifene and diethylstilbestrol (DES). Although the clinical relevance of these changes is unknown, some of them, especially vaginal adenosis, are similar to those seen in young women who were exposed to DES in-utero and who have a 1 in 1000 risk of developing clear-cell carcinoma of the vagina or cervix.

Only a small number of pregnant women have been exposed to tamoxifen. Such exposure has not been reported to cause subsequent vaginal adenosis or clear-cell carcinoma of the vagina or cervix in young women exposed in utero to tamoxifen.

Women should be advised not to become pregnant whilst taking tamoxifen and should use barrier or other non-hormonal contraceptive methods if sexually active. Pre-menopausal patients must be carefully examined before treatment to exclude pregnancy. Women should be informed of the potential risks to the foetus, should they become pregnant whilst taking tamoxifen or within two months of cessation of therapy.

Nursing mothers

It is unknown whether tamoxifen is excreted in human milk and therefore the drug is not recommended during lactation. The decision either to discontinue nursing or discontinue tamoxifen should take into account the importance of the drug to the mother.

Effects on ability to drive and use machines

Tamoxifen has no or negligible influence on the ability to drive or operate machinery. However, fatigue has been reported with the use of tamoxifen and caution should be observed when driving or using machinery while such symptoms persist.

Adverse reactions


List of adverse reactions

Unless specified, the following frequency categories were calculated from the number of adverse events reported in a large phase III study conducted in 9366 postmenopausal women patients with operable breast cancer treated for 5 years and, unless specified, no account was taken of the frequency within the comparative treatment group or whether the investigator considered it to be related to study medication. The safety findings in the breast cancer prevention trials appeared consistent overall with the established safety profile of tamoxifen.

Very common (≥1/10), Common (≥1/100 to <1/10), Uncommon (≥1/1,000 to <1/100), Rare ≥1/10,000 to <1/1,000), Very rare (<1/10,000) including isolated reports

Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Common: Uterine fibroids

Uncommon: Endometrial cancer

Rare: Uterine sarcoma (mostly malignant mixed Mullerian tumours)a, Tumour flarea

Blood and lymphatic system disorders

Common: Anaemia

Uncommon: Thrombocytopenia, Leucopenia, in association with anaemia and/or thrombocytopenia.

Rare: Neutropeniaa (this can sometimes be severe), Agranulocytosisa, Transient falls in platelet counts usually between 80,000-90,000 per cu mm but occasionally lower have been reported in patients taking tamoxifen for breast cancer

Very rare: The tendency towards thrombophlebitis may increase and transient thrombocytopenia may occur.

Immune system disorders

Common: Hypersensitivity reactions

Metabolism and nutrition disorders

Very common: Fluid retention

Uncommon: Hypercalcaemia (in patients with bone metastases) on initiation of therapy

Nervous system disorders

Common: Ischaemic cerebrovascular events, Headache, Light-headedness, Sensory disturbances (including paraesthesia and dysgeusia)

Rare: Optic neuritis*

Eye disorders

Common: Cataracts$, Retinopathy$

Uncommon: Visual disturbance$

Rare: Corneal changes$, Optic neuropathya*

Vascular disorders

Very common: Hot flushes

Common: Thrombo-embolic events (including deep vein thrombosis and microvascular thrombosis). Risks are increased when tamoxifen is used in combination with cytotoxic agents.

Respiratory thoracic and mediastinal disorders

Common: Thrombo-embolic events (including pulmonary embolism). Risk is increased when tamoxifen is used in combination with cytotoxic agents.

Uncommon: Interstitial pneumonitis

Gastrointestinal disorders

Very common: Nausea

Common: Vomiting, Diarrhoea, Constipation

Uncommon: Pancreatitis%

Hepatobiliary disorders

Common: Changes in liver enzyme, Fatty liver&

Uncommon: Cirrhosis of the liver&

Rare: Cholestasisa&, Hepatitis&, Hepatic failurea&, Hepatocellular injurya&, Hepatic necrosisa&

Skin and subcutaneous tissue disorders

Very common: Skin rash

Common: Alopecia

Rare: Angioedema, Stevens-Johnson syndromea, Cutaneous vasculitisa, Bullous pemphigoida, Erythema multiformea

Very rare: Cutaneous lupus erythematosusb

Musculoskeletal and connective tissue disorders

Common: Leg cramp, Myalgia

Reproductive system and breast disorders

Very common: Vaginal bleeding, Vaginal discharge

Common: Pruritus vulvae, Endometrial changes (including hyperplasia and polyps)

Rare: Suppression of menstruation in premenopausal women, Endometriosisa, Cystic ovarian swellinga, Vaginal polyps

Congenital, familial and genetic disorders

Very rare: Porphyria cutanea tardab

General disorders and administration site conditions

Very common: Fatigue

Common: Tumour pain

Investigations

Common: Increase of serum triglyceride%

Injury, poisoning and procedural complications

Very rare: Radiation Recallb

a This adverse drug reaction was not reported in the tamoxifen arm (n=3094) of the above study; however, it has been reported in other trials or from other sources. The frequency has been calculated using the upper limit of the 95% confidence interval for the point estimate (based on 3/X, where X represents the total sample size e.g. 3094). This is calculated as 3/3094 which equates to a frequency category of ‘rare’.
b The event was not observed in other major clinical studies. The frequency has been calculated using the upper limit of the 95% confidence interval for the point estimate (based on 3/X, where X represents the total sample size of 13,357 patients in the major clinical studies). This is calculated as 3/13,357 which equates to a frequency category of ‘very rare’.
* Cases of optic neuropathy and optic neuritis have been reported in patients receiving tamoxifen and, in a small number of cases, blindness has occurred.
& Tamoxifen has been associated with changes in liver enzyme levels and with a spectrum of more severe liver abnormalities which in some cases were fatal, including fatty liver, cholestasis and hepatitis, liver failure, cirrhosis, and, hepatocellular injury (including hepatic necrosis).
% Elevation of serum triglyceride levels, in some cases with pancreatitis, may be associated with the use of tamoxifen.
$ Visual disturbance such as cataracts, retinopathy and corneal changes, mainly in patients treated with exceptionally high doses for a long period of time.

Side effects can be classified as either due to the pharmacological action of the drug, e.g. hot flushes, vaginal bleeding, vaginal discharge, pruritus vulvae and tumour flare, or as more general side effects, e.g. gastrointestinal intolerance, headache, light-headedness and occasionally, fluid retention and alopecia.

When side effects are severe, it may be possible to control them by a simple reduction of dosage (to not less than 20 mg/day) without loss of therapeutic effect. Persistent side effects may necessitate the discontinuance of treatment.

Primary prevention of breast cancer risk

The most common adverse events reported from studies in women at increased risk of breast cancer, and occurring more frequently during treatment with tamoxifen than with placebo, were those associated specifically with the pharmacological action of tamoxifen such as vasomotor symptoms (hot flushes, night sweats), menstrual abnormalities\irregularities, vaginal discharge, and vaginal dryness.

In the primary prevention trials tamoxifen significantly increased the incidence of endometrial cancer, deep vein thrombosis, and pulmonary embolism compared with placebo, but the absolute increase in risk was small. The risk of developing cataracts was also significantly increased with tamoxifen.

Women under 50 years old

A meta-analysis of risk reduction trials stratified by age showed that while women over 50 years old at randomisation had a significantly increased risk of endometrial cancer compared with placebo (RR 3.32, 95% CI 1.95-5.67; p<0.0001), women aged under 50 years did not have a significantly increased risk of pulmonary embolism compared with placebo (RR 1.16, 95% CI 0.55-2.43; p=0.60) and their risk of deep vein thrombosis was only significantly increased during the active treatment phase (RR 2.30, 95% CI 1.23-4.31; p=0,009) but not after treatment had ended.

Gynaecological conditions and procedures

In placebo controlled trials of the use of tamoxifen for the primary reduction of breast cancer risk, benign gynaecological conditions and procedures were more commonly reported with tamoxifen. The IBIS-1 trial found that in 3573 women taking tamoxifen compared to 3566 women on placebo, the following gynaecological conditions and procedures were more common in women taking tamoxifen: abnormal bleeding (842 v 678, p<00001); endometrial polyps (130 v 65, p<0,0001); ovarian cysts (101 v 42, p<00001); hysteroscopy (228 v 138, P<0,0001); pelvic ultrasound (209 v 132, p<00001); dilation and curettage (178 v 94, p<00001); hysterectomy (154 v 104, p=0002) and oophorectomy (103 v 67, p=0006).

Cross-check medications

Review your medication to ensure that there are no potentially harmful drug interactions or contraindications.

Ask the Reasoner

Related medicines

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.